Quotient Clinical Completes Innovative First-In-Human Program
News Apr 23, 2015
Quotient Clinical has announced the publication of results from an Enabled-First-in-Human (Enabled-FIH) program conducted for the Janssen WAVE Early Development unit. The integrated pharmaceutical development and first-in-human clinical program was designed to develop an optimal oral formulation, in parallel with the assessment of single and multiple dose safety, pharmacokinetics and pharmacodynamics of a highly selective small molecule c-Met tyrosine kinase inhibitor.
The clinical phase, which was conducted under a single, adaptive protocol, was completed in only six months. The single ascending dose phase began with a simple solution, and the protocol included the option to assess the relative bioavailability of up to two solid oral dosage formulations.
The transition from solution to a solid dosage form was successfully achieved and this product was used to complete the remaining single and multiple doses. The clinical protocol also included flexible options to assess food effect, dosing frequency and administration to older subjects. Dose proportional increases in exposure were observed and all doses were safe and well tolerated.
Mark Egerton, CEO of Quotient Clinical, commented: “We were very pleased to undertake this program. This is an excellent example of how our innovative Enabled-FIH service can support and accelerate an early development program. Timelines are shortened and the consumption of drug substance is reduced by >85 % compared to a conventional program, delivering significant cost savings. We believe that Enabled-FIH represents an important step forward in helping the industry to improve overall R&D productivity.”
The results will be published on poster CT309 at the American Association of Cancer Research (AACR) 2015 Annual Meeting, Philadelphia, USA. 18-22 April 2015 (Millington DA, Chaplan SR, Aguilar Z et al. Rapid evaluation of a novel small molecule c-Met tyrosine kinase inhibitor in healthy subjects).
Cancer Comes Back All 'Jacked Up' on Stem CellsNews
Recent work increasingly shows that tumors are not static - the populations of cells that make up a tumor evolve over time in response to treatment, often in ways that lead to treatment immunity. Instead of being defined by a snapshot, tumors are more like a movie. This means that a tumor that recurs after treatment may be much different than the tumor originally seen in a biopsy.READ MORE
Exposure to Low Levels of BPA during Pregnancy Can Lead to Altered Brain DevelopmentNews
New research in mice provides an explanation for how exposure to the widely used chemical bisphenol A (BPA) during pregnancy, even at levels lower than the regulated “safe” human exposure level, can lead to altered brain development and behavior later in life.READ MORE
Moving Toward a Future Free of Drug-Induced Hearing LossNews
A new special publication orchestrated by five of the nation's leading hearing experts compiles the latest research into hearing loss caused by drugs and solvents - how it occurs, how to treat it, and how to prevent it.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018